Axogen Reports Strong Q3 2026 Growth Driven by Avance Nerve Graft Demand
Axogen (AXGN) reported robust third-quarter 2026 financial results, highlighted by a 26.2% year-over-year revenue increase to $75.8 million. The growth was primarily driven by strong unit volume demand for the Avance Nerve Graft and significant expansion in the breast reconstruction segment, which saw a 60% increase in growth fueled by new surgeon adoption of the Resensation technique. The company demonstrated improved profitability with adjusted net income rising to $0.21 per share compared to $0.12 in the prior year. Axogen also strengthened its balance sheet following a September equity offering, ending the quarter with $350.1 million in cash and investments. Looking ahead, management raised full-year 2026 revenue guidance to at least $290 million, bolstered by the recent acquisition of BioCircuit.
Tickers: $AXGN
Topics: Adjusted EBITDA Gross Margin Net Income Product Adoption Revenue Growth